![](https://i.imgur.com/HNIfkjO.png)
GOUT

定義 & 流行病學 (_Lancet_ 2016;388:2039)

•Humans lack enzyme to metabolize urate (end-product of purine metabolism)

•MSU crystal deposition promotes inflammation in joints and peri-articular tissue;

•♂ > ♀ (9:1); peak incidence 5th decade; most common cause of inflammatory arthritis in ♂ over 30 y; _rare_ in premenopausal ♀ (estrogens promote renal urate excretion)

原因 (_Ann Rheum Dis_ 2012;71:1448)

•UrA underexcretion (85–90%): meds (eg, diuretics); idiopathic; ↓ renal function; obesity

•Uric acid (UrA) overproduction (10–15%): ↑ meat, seafood, EtOH, psoriasis, idiopathic, myelo- and lymphoproliferative disease, chronic hemolytic anemia, cytotoxic drugs, rare inherited enzyme defic, genetic variants (_Lancet_ 2008;372:1953)

Diagnosis

•↑ **UrA is not diagnostic:** 25% of measurements 正常 during flare; ± ↑ WBC & ESR

•**Arthrocentesis is gold standard:** negatively birefringent needle-shaped MSU crystals

•2015 ACR/EULAR Classification Criteria (_Ann Rheum Dis_ 2015;74:1789) used 1° in research

Acute 治療 (_Ann Rheum Dis_ 2017;76:29)

•No superior option; start within 24 h of sx onset; continue until acute flare resolves; for severe cases, consider combination therapy; rest and ice; without 治療 self-limited in 3–10 d

•Continue urate-lowering therapy during attack if already taking

![](https://i.imgur.com/xVqaAue.png)
Chronic 治療 (_Ann Rheum Dis_ 2017;76:29)

•**Approach:** if ≥2 attacks/y, polyarticular attack, tophus, joint erosions, GFR <60, or urolithiasis → start urate-lowering therapy + pharmacologic ppx to ↓ risk of acute attacks

•**Urate-lowering therapy (ULT):** goal UrA <6 mg/dL or < 5 mg/dl if tophi; when starting ULT, always give with pharm ppx as below; _do NOT d/c during acute attack or due to AKI_

•**Pharmacologic prophylaxis:** continue 6 mo with above Rx or longer if frequent attacks:

low-dose **colchicine** (~50% ↓ risk of acute flare; _J Rheum_ 2004;31:2429), **NSAIDs** (less evidence; _Ann Rheum Dis_ 2006;65:1312), low-dose **steroids**, **IL-1 inhibitors** (see above)

•**Lifestyle** Δs (_Rheum Dis Clin NA_ 2014;40:581): ↓ intake of meat, EtOH & seafood, ↑ low-fat dairy products, wt loss, avoid dehydration

![](https://i.imgur.com/8unxkGs.png)

**Allopurinol hypersensitivity syndrome:** 10–25% mortality; ↓ risk by _starting_ with dose 100 mg/d if eGFR >40 or 50 mg/d if eGFR ≤40; titrate up by 100 mg/d (if eGFR >40) or 50 mg/d (if eGFR ≤40) q2–5wk until UrA <6 mg/dL (dose can be >300 mg/d even in CKD). _Associated with HLA-B5801_, esp. Han Chinese, Koreans, Thai; screen in these high-risk populations prior to initiating allopurinol (_Curr Opin Rheumatol_ 2014;26:16).

CALCIUM PYROPHOSPHATE DIHYDRATE (CPPD) DEPOSITION DISEASE/PSEUDOGOUT

定義

•Deposition of CPPD crystals within tendons, ligaments, articular capsules, synovium, cartilage; frequently asymptomatic

原因 (_Rheumatology_ 2012;51:2070)

•Most cases **_idiopathic_;** consider further metabolic eval in young (<50 y) and florid forms

•Metabolic (_3 H’s_): hemochromatosis; hyperparathyroidism; hypomagnesemia (esp. in Gitelman’s or Bartter’s syndromes)

•Joint trauma (incl. previous surgery); intra-articular hyaluronate can precipitate attacks

•Familial chondrocalcinosis (autosomal dominant disorder); early-onset, polyarticular dis.

臨床表現 (_Rheum Dis Clin NA_ 2014;40:207)

•**Chondrocalcinosis:** calcification of cartilage, resulting from CPPD deposition in articular cartilage, fibrocartilage or menisci

↑ incidence with age; 20% >60 y have knee chondrocalcinosis in autopsy studies

•**Pseudogout:** acute CPPD crystal-induced mono- or asymmetric oligoarticular arthritis, _indistinguishable from gout except through synovial fluid exam for crystals_

location: **knees**, **wrists** and MCP joints

precipitants: surgery, trauma, or severe illness

•Chronic forms: “pseudo-RA” and pyrophosphate arthropathy (may involve axial skeleton, resembles OA)

Diagnostic studies

•Arthrocentesis is gold standard: **rhomboid shaped, weakly _positively_ birefringent crystals** (yellow _perpendicular_ & blue _parallel_ to axis on polarizer; see table above)

•Radiographs: see table above

治療 (_NEJM_ 2016;374:2575)

•Asymptomatic chondrocalcinosis requires no 治療

•Acute therapy for pseudogout: no RCTs, extrapolated from practice in gout; ∴ same as for gout, though colchicine not as effective

•If associated metabolic disease, Rx of underlying disorder _may_ improve arthritis sx

•Low-dose daily colchicine or NSAID may be effective for prophylaxis or chronic arthropathy

